A European survey of management approaches in chronic urticaria in children: EAACI pediatric urticaria taskforce.
child
chronic urticaria
omalizumab
urticaria diagnosis
urticaria treatment
Journal
Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology
ISSN: 1399-3038
Titre abrégé: Pediatr Allergy Immunol
Pays: England
ID NLM: 9106718
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
revised:
21
09
2021
received:
12
08
2021
accepted:
27
09
2021
pubmed:
4
10
2021
medline:
18
3
2022
entrez:
3
10
2021
Statut:
ppublish
Résumé
Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0-18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for pediatric urticaria are implemented. The EAACI Task Force for pediatric CU disseminated an online clinical survey among EAACI pediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centers. The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly pediatric allergists (80%) and pediatricians (49.7%), working in 69 countries. For diagnosis, Southern European countries used significantly more routine tests (eg, autoimmune testing, allergological tests, and parasitic investigation) than Northern European countries. Most respondents (60.3%) used a 2 Even though most members of the Pediatric Section of EAACI are familiar with the EAACI/WAO/GA2LEN/EDF guidelines, a significant number do not follow them. Also, the large variation in diagnosis and treatment strengthens the need to re-evaluate, update, and standardize guidelines on the diagnosis and management of CU in children.
Sections du résumé
BACKGROUND
Although well described in adults, there are scarce and heterogeneous data on the diagnosis and management of chronic urticaria (CU) in children (0-18 years) throughout Europe. Our aim was to explore country differences and identify the extent to which the EAACI/GA²LEN/EDF/WAO guideline recommendations for pediatric urticaria are implemented.
METHODS
The EAACI Task Force for pediatric CU disseminated an online clinical survey among EAACI pediatric section members. Members were asked to answer 35 multiple choice questions on current practices in their respective centers.
RESULTS
The survey was sent to 2,773 physicians of whom 358 (13.8%) responded, mainly pediatric allergists (80%) and pediatricians (49.7%), working in 69 countries. For diagnosis, Southern European countries used significantly more routine tests (eg, autoimmune testing, allergological tests, and parasitic investigation) than Northern European countries. Most respondents (60.3%) used a 2
CONCLUSIONS
Even though most members of the Pediatric Section of EAACI are familiar with the EAACI/WAO/GA2LEN/EDF guidelines, a significant number do not follow them. Also, the large variation in diagnosis and treatment strengthens the need to re-evaluate, update, and standardize guidelines on the diagnosis and management of CU in children.
Substances chimiques
Histamine H1 Antagonists
0
Omalizumab
2P471X1Z11
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13674Informations de copyright
© 2021 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
Références
Maurer M, Gimenez-Arnau A, Ensina LF, Chu CY, Jaumont X, Tassinari P. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results. World Allergy Organ J. 2020;13(9):100460. https://doi.org/10.1016/j.waojou.2020.100460
Goncalo M, Gimenez-Arnau A, Al-Ahmad M, et al. The global burden of chronic urticaria for the patient and society. Br J Dermatol. 2021;184(2):226-236. https://doi.org/10.1111/bjd.19561
Balp MM, Khalil S, Tian H, Gabriel S, Vietri J, Zuberbier T. Burden of chronic urticaria relative to psoriasis in five European countries. J Eur Acad Dermatol Venereol. 2018;32(2):282-290. https://doi.org/10.1111/jdv.14584
Itakura A, Tani Y, Kaneko N, Hide M. Impact of chronic urticaria on quality of life and work in Japan: results of a real-world study. J Dermatol. 2018;45(8):963-970. https://doi.org/10.1111/1346-8138.14502
Maurer M, Abuzakouk M, Berard F, et al. The burden of chronic spontaneous urticaria is substantial: real-world evidence from ASSURE-CSU. Allergy. 2017;72(12):2005-2016. https://doi.org/10.1111/all.13209
Thomsen SF, Pritzier EC, Anderson CD, et al. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study. J Eur Acad Dermatol Venereol. 2017;31(6):1048-1055. https://doi.org/10.1111/jdv.14210
Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-1414. https://doi.org/10.1111/all.13397
United Nations publication "Standard Country or Area Codes for Statistical Use". https://unstats.un.org/unsd/methodology/m49/. Accessed January 5, 2021.
Hawro T, Ohanyan T, Schoepke N, et al. The urticaria activity score-validity, reliability, and responsiveness. J Allergy Clin Immunol Pract. 2018;6(4):1185-1190.e1. https://doi.org/10.1016/j.jaip.2017.10.001
Weller K, Groffik A, Church MK, et al. Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control. J Allergy Clin Immunol. 2014;133(5):1365-1372, 1372 e1-6. https://doi.org/10.1016/j.jaci.2013.12.1076
Volonakis M, Katsarou-Katsari A, Stratigos J. Etiologic factors in childhood chronic urticaria. Ann Allergy. 1992;69(1):61-65.
Maurer M, Church MK, Goncalo M, Sussman G, Sanchez-Borges M. Management and treatment of chronic urticaria (CU). J Eur Acad Dermatol Venereol. 2015;29(Suppl 3):16-32. https://doi.org/10.1111/jdv.13198
Balp MM, Weller K, Carboni V, et al. Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. Pediatr Allergy Immunol. 2018;29(6):630-636. https://doi.org/10.1111/pai.12910
Powell RJ, Leech SC, Till S, et al. BSACI guideline for the management of chronic urticaria and angioedema. Clin Exp Allergy. 2015;45(3):547-565. https://doi.org/10.1111/cea.12494
Caffarelli C, Paravati F, El Hachem M, et al. Management of chronic urticaria in children: a clinical guideline. Ital J Pediatr. 2019;45(1):101. https://doi.org/10.1186/s13052-019-0695-x
Costa C, Goncalo M, Urticaria GGPdEd. [Diagnostic and therapeutic approach of chronic spontaneous urticaria: recommendations in Portugal]. Acta Med Port. 2016;29(11):763-781. Abordagem Diagnostica e Terapeutica da Urticaria Cronica Espontanea: Recomendacoes em Portugal. https://doi.org/10.20344/amp.8294
Curto-Barredo L, Yelamos J, Gimeno R, Mojal S, Pujol RM, Gimenez-Arnau A. Basophil activation test identifies the patients with chronic spontaneous urticaria suffering the most active disease. Immun Inflamm Dis. 2016;4(4):441-445. https://doi.org/10.1002/iid3.125
Hoffmann HJ, Santos AF, Mayorga C, et al. The clinical utility of basophil activation testing in diagnosis and monitoring of allergic disease. Allergy. 2015;70(11):1393-1405. https://doi.org/10.1111/all.12698
Sahiner UM, Civelek E, Tuncer A, et al. Chronic urticaria: etiology and natural course in children. Int Arch Allergy Immunol. 2011;156(2):224-230. https://doi.org/10.1159/000322349
Church MK, Weller K, Stock P, Maurer M. Chronic spontaneous urticaria in children: itching for insight. Pediatr Allergy Immunol. 2011;22(1 Pt 1):1-8. https://doi.org/10.1111/j.1399-3038.2010.01120.x
Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65(4):459-466. https://doi.org/10.1111/j.1398-9995.2009.02325.x
Broder MS, Raimundo K, Antonova E, Chang E. Resource use and costs in an insured population of patients with chronic idiopathic/spontaneous urticaria. Am J Clin Dermatol. 2015;16(4):313-321. https://doi.org/10.1007/s40257-015-0134-8
Zuberbier T, Aberer W, Asero R, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA2 LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014;69(7):e1-e29. https://doi.org/10.1111/all.12370
European Medicines Evaluation Agency (EMEA). Omalizumab (Xolair) summary of product characteristics (SmPC). http://www.ema.europa.eu. Accessed June 30, 2017.
Maurer M, Eyerich K, Eyerich S, et al. Urticaria: collegium internationale allergologicum (CIA) update 2020. Int Arch Allergy Immunol. 2020;181(5):321-333. https://doi.org/10.1159/000507218
Khaleva E, Vazquez-Ortiz M, Comberiati P, et al. Current transition management of adolescents and young adults with allergy and asthma: a European survey. Clin Transl Allergy. 2020;10:40. https://doi.org/10.1186/s13601-020-00340-z
Roberts G, Vazquez-Ortiz M, Knibb R, et al. EAACI Guidelines on the effective transition of adolescents and young adults with allergy and asthma. Allergy. 2020;75(11):2734-2752. https://doi.org/10.1111/all.14459
Bauer A, Dickel H, Jakob T, et al. Expert consensus on practical aspects in the treatment of chronic urticaria. Allergo J Int. 2021;30(2):64-75. https://doi.org/10.1007/s40629-021-00162-w
Hacard F, Giraudeau B, d'Acremont G, et al. Guidelines for the management of chronic spontaneous urticaria: recommendations supported by the centre of evidence of the French society of dermatology. Br J Dermatol. 2021;185(3):658-660. https://doi.org/10.1111/bjd.20415
Song WJ, Choi M, Lee DH, et al. The KAAACI/KDA evidence-based practice guidelines for chronic spontaneous urticaria in Korean adults and children: part 1. definition, methodology and first-line management. Allergy Asthma Immunol Res. 2020;12(4):563-578. https://doi.org/10.4168/aair.2020.12.4.563
Katelaris C, Smith W & Choi J et al. ASCIA chronic spontaneous urticaria (CSU) position paper and treatment guidelines. https://www.allergy.org.au/images/stories/pospapers/ASCIA_HP_Position_Paper_CSU_2020.pdf.
Beck LA, Bernstein JA, Maurer M. A review of international recommendations for the diagnosis and management of chronic urticaria. Acta Derm Venereol. 2017;97(2):149-158. https://doi.org/10.2340/00015555-2496
Kulthanan K, Tuchinda P, Chularojanamontri L, et al. Clinical practice guideline for diagnosis and management of urticaria. Asian Pac J Allergy Immunol. 2016;34(3):190-200.
Kocatürk Göncü E, Aktan S, Atakan N, et al. The Turkish guideline for the diagnosis and management of urticaria-2016. Turkderm - Arch Turk Dermatol Venerology. 2016;50:82-98. https://doi.org/10.4274/turkderm.22438
Bernstein JA, Lang DM, Khan DA, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol. 2014;133(5):1270-1277. https://doi.org/10.1016/j.jaci.2014.02.036
Hide M, Hiragun T, Japanese DA. Japanese guidelines for diagnosis and treatment of urticaria in comparison with other countries. Allergol Int. 2012;61(4):517-527. https://doi.org/10.2332/allergolint.12-RAI-0497